EANS-News: Intercell AG / Intercell launches Level I ADR program in the Unites States

» ADRs to provide a more convenient way for US investors to

invest in Intercell

» Each ADR will represent one Intercell AG ordinary share

» Intercell's shares are listed and will continue to trade on the

Vienna Stock Exchange (VSE) - ADRs are expected to be quoted on

the OTCQX International market under the symbol "INRLY"

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

finances

Wien (euro adhoc) - Vienna (Austria), May 7, 2009 - Intercell AG
announced today that it has launched a sponsored Level I American
Depositary Receipt (ADR) facility in the United States. The Bank of
New York Mellon has been appointed as the Company's depositary bank
for this facility and will start issuing U.S. dollar denominated ADRs
as of today. Each ADR will represent one Intercell AG ordinary share.

Intercell's shares are listed and will continue to trade on the
Vienna Stock Exchange (VSE). To enhance trading of its ADRs,
Intercell has applied to have its ADRs quoted on the OTCQX
International market, a leading electronic listing and disclosure
platform for qualified foreign issuers on the U.S. over-the-counter
(OTC) securities market. Intercell ADRs will trade under the symbol
"INRLY".

"The ADR program is an additional step to expand our reach to
investors in the United States," said Reinhard Kandera, Intercell's
Chief Financial Officer. "We have recently received U.S. approval for
our first product - IXIARO, a novel vaccine against Japanese
Encephalitis, - we have a sizable U.S. research and development
operation in Gaithersburg, Maryland, and our advanced clinical
pipeline in the area of hospital-acquired infections and patch
vaccines has received a lot of attention from U.S. healthcare equity
investors. The launch of an ADR program and the OTCQX quotation are
logical next steps to further develop our relationship with current
and future U.S. shareholders."

About ADRs

An American Depositary Receipt (ADR) is a negotiable U.S. security
that represents a company's publicly traded equity or debt.
Depositary Receipts are created when a broker purchases a non-U.S.
company's shares on its home stock market and delivers the shares to
the depositary's local custodian bank, and then instructs the
depositary bank, such as The Bank of New York Mellon, to issue
Depositary Receipts. In addition, Depositary Receipts may also be
purchased in the U.S. secondary trading market. Level I ADRs may
trade freely just like any other security in the over-the-counter
(OTC) market. More information on ADRs is available at
www.adrbnymellon.com.

About OTCQX

OTCQX provides a gateway to U.S. securities markets for international
companies that are listed on a qualified non-U.S. exchange and
provide ongoing disclosure in English to U.S. investors. More
importantly, OTCQX distinguishes the reputable international issuers
from the 9,000 over-the-counter (OTC) securities traded in the United
States. OTCQX quotation is not a stock exchange listing, and issuers
are not subject to regulatory requirements such as Sarbanes Oxley
compliance or U.S.-GAAP reporting. For more information about OTCQX,
visit www.otcqx.com.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market